← Who reports today · Health Care
INCY · Q2 2026
Archived report (Q2 2026). Latest deep dive →
Net income
$586M
up 44.6% y/y
Total revenues
$1,674M
up 37.7% y/y
Income from operations
$698M
up 31.6% y/y
The quarter in brief
Incyte's revenue grew 37.7% to $1.67B, operating income rose 31.6% to $697.9M and net income 44.6% to $585.6M; diluted EPS was $2.81 versus $2.04.
- Income from operations +31.6% — revenue growth, including $246 million of additional Opzelura sales from the CMS agreement
Source
«GAAP and Non-GAAP operating income for the quarter ended June 30, 2026 increased 32% and 102%, respectively, compared to the same period in 2025, driven primarily by growth in total revenue, including the impact of the $246 million of additional net sales of Opzelura relating to the aforementioned CMS agreement»
press release, 8-K
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net sales | $1,488 · +40.5% |
| Product royalty revenues | $175 · +15.6% |
| Milestone and contract revenues | $11.2 · +124% |
| Total revenues | $1,674 · +37.7% |
| Cost of sales (including definite-lived intangible amortization) | $105 · +33.3% |
| Research and development | $517 · +4.5% |
| Selling, general and administrative | $352 · +6.3% |
| Loss on change in fair value of acquisition-related contingent consideration | $2.5 · −89.0% |
| Income from operations | $698 · +31.6% · 41.7% margin |
| Interest income | $38.1 · +51.6% |
| Interest expense | $0.6 · −2.0% |
| Gain (loss) on equity investments | $9.8 · vs −$4.2 |
| Other, net | $6.3 · −14.1% |
| Income before provision for income taxes | $752 · +34.7% |
| Provision for income taxes | $166 · +8.4% · 22.1% effective rate |
| Net income | $586 · +44.6% · $2.81/sh · 35.0% margin |
Verdict: Incyte's revenue grew 37.7% to $1.67B, operating income rose 31.6% to $697.9M and net income 44.6% to $585.6M; diluted EPS was $2.81 versus $2.04.
Source and notation
Source: INCY press release, 8-K EX-99.1 of 07/28/2026 (SEC EDGAR).
Open as an image: INCY, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “INCY Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/incy/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/incy/q2-2026"><img src="https://whoreportstoday.com/t/incy/q2-2026/sankey.png" alt="INCY Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/incy/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/incy/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/incy/q2-2026">INCY Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Total net sales of $1.49 billion increased 40%, and excluding the one-time, non-cash Opzelura benefit related to the CMS settlement they grew 17%.
- Operating income was $698M (+31.6% y/y), an operating margin of 41.7% vs 43.6% a year ago.
- Income tax of $166M implies an effective rate of 22.1% vs 27.4% a year ago.
- Diluted EPS was $2.81 vs $2.04 a year ago (+37.7%), while net income changed +44.6%.
What distorts the picture in this report and what to watch beyond the headlines.
INCY — a biopharmaceutical company that discovers, develops and sells its own medicines in hematology, oncology, and inflammation and autoimmunity, including JAKAFI, OPZELURA cream and MONJUVI.
It earns money from product sales and from royalties and milestones paid by partners, such as on sales of JAKAVI outside the U.S.; the company reports a single segment. · Source: annual report (Form 10-K, SEC)
More reports: IQV · Q3 2026 · ISRG · Q3 2026 · JNJ · Q3 2026 · LH · Q3 2026 · LLY · Q3 2026 · MCK · Q2 FY2027 · MDT · Q1 2027 · MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · all reports